Monday, July 9, 2012

DNS root zone


From Wikipedia, the free encyclopedia
Jump to: navigation, search
A DNS root zone is the top-level DNS zone in a hierarchical namespace using the Domain Name System (DNS) for computers. Most commonly it refers to the root zone of the largest global network, the Internet.
The US Department of Commerce NTIA exercises the ultimate authority over the DNS root zone of the Internet.[1] The zone is managed by the Internet Assigned Numbers Authority (IANA) as the operator while a third party is contracted by the NTIA as the root zone maintainer. The IANA operator is ICANN and the root zone maintainer is Verisign, Inc.
A combination of limits in the DNS definition and in certain protocols, namely the practical size of unfragmented User Datagram Protocol (UDP) packets, resulted in a limited number of root server addresses that can be accommodated in DNS name query responses. This limit has determined the number of name server installations at (currently) 13 clusters, serving the needs of the entire public Internet worldwide.

Contents

Initialization of DNS service

There are thirteen root server clusters that are authoritative for queries to the global DNS root zone. The root servers hold the lists of names and addresses for the authoritative servers for all top-level domains. Every name lookup must either start with a query to a root server or use information that was once obtained from a root server.
The root servers have the official names a.root-servers.net to m.root-servers.net. However, to look up the IP address of a root server from these names, a DNS resolver must first be able to look up a root server to find the address of an authoritative server for the .net DNS zone. Clearly this creates a circular dependency, so the address of at least one root server must be known by a host in order to bootstrap access to the DNS. This is usually done by shipping the addresses of all known DNS root servers as a file with the computer operating system: the IP addresses of some root servers will change over the years, but only one correct address is needed for the resolver to obtain the current list of name servers. This file is called named.cache in the BIND nameserver reference implementation and a current version is officially distributed by ICANN's InterNIC.[2]
Once the address of a single functioning root server is known, all other DNS information can be discovered recursively, and the address of any domain name may be found.

Redundancy and diversity

The root DNS servers are essential to the function of the Internet, as most Internet services, such as the World-Wide Web and electronic mail, are based on domain names. The DNS servers are potential points of failure for the entire Internet. For this reason, there are multiple root servers worldwide. The number has been limited to 13 in DNS responses because DNS was limited to 512-byte packets until protocol extensions (EDNS) were designed to lift this restriction. While it is possible to fit more entries into a packet of this size when using "label compression", 13 was chosen as a reliable limit. Since the introduction of IPv6, the next-generation Internet Protocol, previous practices are being modified and extra space is filled with IPv6 name servers.
The root name servers are hosted in multiple secure sites with high-bandwidth access to accommodate the traffic load. At first, all of these installations were located in the United States. However, the distribution has shifted and this is no longer the case. Usually each DNS server installation at a given site is physically a cluster of machines with load-balancing routers. A comprehensive list of servers, their locations, and properties is available at http://root-servers.org. As of May 2011 there were 242 root servers worldwide.
The modern trend is to use anycast addressing and routing to provide resilience and load balancing across a wide geographic area. For example, the j.root-servers.net root server, maintained by VeriSign, is represented by 41 (as of July 2008) individual server systems located around the world, which can be queried using anycast addressing.[citation needed]

Management

The content of the root zone file is controlled by ICANN (Internet Corporation for Assigned Names and Numbers), which now operates the Internet Assigned Numbers Authority (IANA). Changes must also be approved by the US Department of Commerce NTIA. The physical zone file itself is generated and distributed by VeriSign, to the various root server operators.

Source: http://en.wikipedia.org/wiki/DNS_root_zone

Sunday, July 8, 2012

How to Get Rid of Dust Mite Bites




Dust mites are microscopic insects that reside in most homes and offices. Dust mites feed on dead skin cells. Many individuals are allergic to dust mites, often resulting in asthma, skin irritations and chronic allergies. Because dust mites feed on dead skin cells that have been sloughed off, they don't actually bite humans. The allergens produced by dust mites can, however, cause skin reactions that resemble insect bites. If you have this issue, you can treat these bite-like marks via a range of different means. Does this Spark an idea?

Other People Are Reading





Things You'll Need


  • Hydrocortisone cream Antihistamine topical treatments Oral allergy medications Air purifiers

Instructions

    • 1
      Apply hydrocortisone cream to your affected skin. Hydrocortisone cream soothes irritated skin, helping to reduce redness and inflammation. You can find hydrocortisone cream in most drug stores.
    • 2
      Use topical allergy medication. Available over the counter in most drug stores, various topical treatments are used to treat insect bites and itchy skin. Opt for a treatment that contains antihistamines. They help to combat the dust mite allergens that cause the bite-like reactions.
    • 3
      Take oral allergy medications. Because these marks that resemble dust mite bites are caused by allergens, oral allergy medication can remedy the issue. There are many varieties available over the counter. If you have severe allergies, talk to your doctor about prescription-strength allergy medication.
    • 4
      Do not scratch or pick at your irritated skin. Doing so can worsen the irritation and bite-like marks. Scratching or picking at your skin can even permanently damage your skin, leading to scarring.
    • 5
      Use an air purifier. Air purifiers filter the air you breathe, removing dust mite allergens that can lead to your irritated skin. Avoid humidifiers that moisten the air; dust mites thrive in humid environments.
    • 6
      See a doctor if your skin doesn't recover within a few days. Your irritated skin may be due to a more serious underlying issue, such as a skin infection.



Tips & Warnings

  • Regularly wash your bedding and clothes in hot water to reduce the likelihood of dust mite infestation.

Read more: How to Get Rid of Dust Mite Bites | eHow.com http://www.ehow.com/how_5101949_rid-dust-mite-bites.html#ixzz200trk9JO

Source: www.ehow.com

Zolpidem or Stilnox effect

Zolpidem

From Wikipedia, the free encyclopedia
  (Redirected from Stilnox)
Jump to: navigation, search
Zolpidem
Systematic (IUPAC) name
N,N-dimethyl-2-(6-methyl-2-p-tolylimidazo[1,2-a]pyridin-3-yl)acetamide
Clinical data
Trade names Ambien
AHFS/Drugs.com monograph
MedlinePlus a693025
Pregnancy cat. B3 (AU) C (US)
Legal status Schedule IV (US) POM (UK)[1]
Routes Oral (tablet), Sublingual, Oromucosal (spray)
Pharmacokinetic data
Bioavailability 70% (oral) 92% bound in plasma
Metabolism HepaticCYP3A4
Half-life 2 to 3 hours
Excretion 56% renal
34% fecal
Identifiers
CAS number 82626-48-0 Yes
ATC code N05CF02
PubChem CID 5732
DrugBank DB00425
ChemSpider 5530 Yes
UNII 7K383OQI23 Yes
KEGG D08690 Yes
ChEBI CHEBI:10125 
ChEMBL CHEMBL911 Yes
Chemical data
Formula C19H21N3O 
Mol. mass 307.395 g/mol
  (what is this?)  (verify)
Zolpidem (sold under the brand names Ambien, Ambien CR, Stilnox, and Sublinox) is a prescription medication used for the treatment of insomnia, as well as some brain disorders. It is a short-acting nonbenzodiazepine hypnotic of the imidazopyridine class [2] that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to GABAA receptors at the same location as benzodiazepines.[3] It works quickly (usually within 15 minutes) and has a short half-life (two to three hours).
Zolpidem has not adequately demonstrated effectiveness in maintaining sleep (unless delivered in a controlled-release form); however, it is effective in initiating sleep.[4] Its hypnotic effects are similar to those of the benzodiazepine class of drugs, but it is molecularly distinct from the classical benzodiazepine molecule and is classified as an imidazopyridine. Flumazenil, a benzodiazepine receptor antagonist, which is used for benzodiazepine overdose, can also reverse zolpidem's sedative/hypnotic and memory-impairing effects.[5][6]
As an anticonvulsant and muscle relaxant, the drug's effects aren't evident until dosages 10 and 20 times those required for sedation, respectively, are reached.[7] For that reason, zolpidem has never been approved for either muscle relaxation or seizure prevention. Such drastically increased doses are also more inclined to induce one or more of the drug's adverse side effects, including hallucinations and amnesia.
The patent in the United States on zolpidem was held by the French pharmaceutical corporation Sanofi-Aventis.[8] On April 23, 2007, the U.S. Food and Drug Administration (FDA) approved 13 generic versions of zolpidem tartrate.[9] Zolpidem is available from several generic manufacturers in the UK, as a generic from Sandoz in South Africa and TEVA in Israel, as well as from other manufacturers such as Ratiopharm (Germany).

Contents

Medical uses

Zolpidem tartrate 10 mg tablets
Zolpidem is used for short-term (usually about two to six weeks) treatment of insomnia.[10] It has been studied for nightly use up to six months in a single-blind trial published in 1991,[11] an open-label study lasting 180 days published in 1992 (with continued efficacy in patients who had kept taking it as of 180 days after the end of the trial),[12] and in an open-label trial lasting 179 days published in 1993.[13] Zolpidem has not proven effective in maintaining sleep and is more used for sleep initiation problems.[4]
Zolpidem is one of the most common GABA-potentiating sleeping medications prescribed in the Netherlands, with a total of 582,660 prescriptions dispensed in 2008.[14]
The United States Air Force uses zolpidem as one of the hypnotics approved as "no-go pills" to help aviators and special duty personnel sleep in support of mission readiness (the other hypnotics used are temazepam and zaleplon during war time). "Ground tests" are required prior to authorization issued to use the medication in an operational situation.[15]
There is evidence that zolpidem can rouse patients from a persistent vegetative state.[16] There has been some evidence of zolpidem being used as a date-rape drug because of its euphoric/hypnotic effect.[citation needed]

Adverse effects

Various zolpidem pills
Side effects may include:
Some users have reported unexplained sleepwalking[18] while using zolpidem, and a few have reported driving, binge eating, sleep talking, and performing other daily tasks while sleeping. Research by Australia's National Prescribing Service found these events occur mostly after the first dose taken, or within a few days of starting therapy.[19] Rare reports of sexual parasomnia episodes related to zolpidem intake have also been reported.[20] Sleepwalkers can sometimes perform these tasks as normally as they might if they were awake. They can sometimes carry on complex conversations and respond appropriately to questions or statements, so much so that observers may believe them to be awake. This is similar to, but unlike, typical sleep talking, which can usually be identified easily and is characterised by incoherent speech that often has no relevance to the situation or that is so disorganised as to be completely unintelligible. Those under the influence of this medication may seem fully aware of their environments, though they are still asleep. This can bring about concerns for the safety of the sleepwalkers and others. These side effects may be related to the mechanism that also causes zolpidem to produce its hypnotic properties.[21] It is unclear whether the drug is responsible for the behavior, but a class-action lawsuit was filed against Sanofi-Aventis in March 2006 on behalf of those who reported symptoms.[22] It is possible some users believe they were asleep during these events because they do not remember the events, due to the short-term memory loss and anterograde amnesia side effects.
Residual 'hangover' effects, such as sleepiness and impaired psychomotor and cognitive function, after nighttime administration may persist into the next day, which may impair the ability of users to drive safely and increase risks of falls and hip fractures.[23]
The Sydney Morning Herald in Australia in 2007 reported a man who fell 30 meters to his death from a high-rise unit balcony may have been sleepwalking under the influence of Stilnox. The coverage prompted over 40 readers to contact the newspaper with their own accounts of Stilnox-related automatism, and as of March 2007, the drug was under review by the Adverse Drug Reactions Advisory Committee.[24]
In February 2008, the Australian Therapeutic Goods Administration attached a Black Box Warning to zolpidem, stating, that "Zolpidem may be associated with potentially dangerous complex sleep-related behaviours that may include sleep walking, sleep driving, and other bizarre behaviours. Zolpidem is not to be taken with alcohol. Caution is needed with other CNS depressant drugs. Limit use to four weeks maximum under close medical supervision."[25] This report received widespread media coverage[26] after the death of Australian student Mairead Costigan, who fell 20 m from the Sydney Harbour Bridge while under the influence of Stilnox.[27]

Tolerance, dependence, and withdrawal

Ambien tablets
A review medical publication found long-term use of zolpidem is associated with drug tolerance, drug dependence, rebound insomnia and CNS-related adverse effects. It was recommended that zolpidem be used for short periods of time using the lowest effective dose. Zolpidem 10 mg is effective in treating insomnia when used intermittently no fewer than three and no more than five pills per week for a period of 12 weeks.[28] The 15-mg zolpidem dosage provided no clinical advantage over the 10-mg zolpidem dosage.[29]
Nonpharmacological treatment options (e.g. cognitive behavioral therapy for insomnia), however, were found to have sustained improvements in sleep quality.[30] Animal studies of the tolerance-inducing properties have shown that in rodents, zolpidem has less tolerance-producing potential than benzodiazepines, but in primates the tolerance-producing potential of zolpidem was the same as that of benzodiazepines.[31] Tolerance to the effects of zolpidem can develop in some people in just a few weeks. Abrupt withdrawal may cause delirium, seizures, or other severe effects, especially if used for prolonged periods and at high dosages.[32][33][34]
When drug tolerance and physical dependence to zolpidem has developed, treatment usually entails a gradual dose reduction over a period of months to minimise withdrawal symptoms, which can resemble those seen during benzodiazepine withdrawal. Failing that, an alternative method may be necessary for some patients, such as a switch to a benzodiazepine equivalent dose of a longer-acting benzodiazepine drug, such as diazepam or chlordiazepoxide, followed by a gradual reduction in dosage of the long-acting benzodiazepine. Sometimes for difficult-to-treat patients, an inpatient flumazenil rapid detoxification program can be used to detoxify from a zolpidem drug dependence or addiction.[35]
Alcohol has cross tolerance with GABAA receptor positive modulators such as the benzodiazepines and the nonbenzodiazepine drugs. For this reason, alcoholics or recovering alcoholics may be at increased risk of physical dependency on zolpidem. Also, alcoholics and drug abusers may be at increased risk of abusing and or becoming psychologically dependent on zolpidem. It should be avoided in those with a history of alcoholism, drug misuse, physical dependency, or psychological dependency on sedative-hypnotic drugs. Zolpidem has rarely been associated with drug-seeking behavior, the risk of which is amplified in patients with a history of drug or alcohol abuse.

Overdose

An overdose of zolpidem may cause excessive sedation, pin-point pupils, or depressed respiratory function, which may progress to coma, and possibly death. Combined with alcohol, opiates, or other CNS depressants, it may be even more likely to lead to fatal overdoses. Zolpidem overdosage can be treated with the benzodiazepine receptor antagonist flumazenil, which displaces zolpidem from its binding site on the benzodiazepine receptor, so rapidly reverses the effects of zolpidem.[36]

Detection in body fluids

Zolpidem may be quantitated in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest, or to assist in a medicolegal death investigation. Blood or plasma zolpidem concentrations are usually in a range of 30–300 μg/l in persons receiving the drug therapeutically, 100–700 μg/l in those arrested for impaired driving, and 1000–7000 μg/l in victims of acute overdosage. Analytical techniques, in general, involve gas or liquid chromatography.[37][38][39]

Special precautions

Driving

Use of zolpidem may impair driving skills with a resultant increased risk of road traffic accidents. This adverse effect is not unique to zolpidem but also occurs with other hypnotic drugs. Caution should be exercised by motor vehicle drivers.[40]

Elderly

The elderly are more sensitive to the effects of hypnotics including zolpidem. Zolpidem causes an increased risk of falls and may induce adverse cognitive effects.[41]
An extensive review of the medical literature regarding the management of insomnia and the elderly found there is considerable evidence of the effectiveness and durability of nondrug treatments for insomnia in adults of all ages, and these interventions are underused. Compared with the benzodiazepines, the nonbenzodiazepine (including zolpidem) sedative-hypnotics appeared to offer few, if any, significant clinical advantages in efficacy or tolerability in elderly persons. Newer agents with novel mechanisms of action and improved safety profiles, such as the melatonin agonists, were found to hold promise for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and has traditionally been discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of these agents remain to be determined. More research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.[42]

Gastroesophageal reflux disease

Patients suffering from gastroesophageal reflux disease had reflux events measured to be significantly longer when taking zolpidem than on placebo. (The same trend was found for reflux events in patients without GERD). This is assumed to be due to suppression of arousal during the reflux event, which would normally result in a swallowing reflex to clear gastric acid from the esophagus. Patients with GERD who take zolpidem thus experience significantly higher esophageal exposure to gastric acid, which increases the likelihood of developing esophageal cancer.[43]

Pregnancy

Zolpidem has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of incomplete ossification and increased postimplantation fetal loss at doses greater than seven times the maximum recommended human dose or higher; however, teratogenicity was not observed at any dose level. There are no controlled data in human pregnancy. In one case report, zolpidem was found in cord blood at delivery. Zolpidem is only recommended for use during pregnancy when benefits outweigh risks. [44]

Mechanism of action

Zolpidem DOJ.jpg
Zaleplon and Zolpidem both are agonists at the GABA A ɣ 1 subunit. Due to its selective binding, Zolpidem has very weak anxiolytic, myorelaxant, and anticonvulsant properties but very strong hypnotic properties.[45] Zolpidem binds with high affinity and acts as a full agonist at the α1-containing GABAA receptors, about 10-fold lower affinity for those containing the α2- and α3- GABAA receptor subunits, and with no appreciable affinity for α5 subunit-containing receptors.[46][47] ω1 type GABAA receptors are the α1-containing GABAA receptors and ω2 GABAA receptors are the α2-, α3-, α4-, α5-, and α6-containing GABAA receptors. ω1 GABAA receptors are found primarily in the brain, whereas ω2 receptors are found primarily in the spine. Thus, zolpidem has a preferential binding for the GABAA-benzodiazepine receptor complex in the brain but a low affinity for the GABAA-benzodiazepine receptor complex in the spine.[48]
Like the vast majority of benzodiazepine-like molecules, zolpidem has no affinity for α4 and α6 subunit-containing receptors.[49] Zolpidem positively modulates GABAA receptors, it is presumed by increasing the GABAA receptor complex's apparent affinity for GABA without affecting desensitization or peak current.[50] Like zaleplon (Sonata), zolpidem may increase slow wave sleep but cause no effect on stage 2 sleep.[51]
A meta-analysis of the randomised, controlled, clinical trials that compared benzodiazepines against Z-drugs such as zolpidem has shown few consistent differences between zolpidem and benzodiazepines in terms of sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.[52]

Drug-drug interactions

Notable drug-drug interactions with the pharmacokinetics of zolpidem include chlorpromazine, fluconazole, imipramine, itraconazole, ketoconazole, rifampicin, and ritonavir. Interactions with carbamazepine and phenytoin can be expected based on their metabolic pathways, but have not yet been studied. There does not appear to be any interaction between zolpidem and cimetidine or ranitidine.[53][54]

Abuse

Recreational use

Zolpidem has a potential for either medical misuse when the drug is continued long term without or against medical advice, or recreational use when the drug is taken to achieve a "high".[55] The transition from medical use of zolpidem to high-dose addiction or drug dependence can occur when used without a doctor's recommendation to continue using it, when physiological drug tolerance leads to higher doses than the usual 5 mg or 10 mg, when consumed through inhalation or injection, or when taken for purposes other than as a sleep aid. Misuse is more prevalent in those who have been dependent on other drugs in the past, but tolerance and drug dependence can still sometimes occur in those without a history of drug dependence. Chronic users of high doses are more likely to develop physical dependence on the drug, which may cause severe withdrawal symptoms, including seizures, if abrupt withdrawal from zolpidem occurs.[56]
As is the case with many prescription sedative/hypnotic drugs, it is sometimes used by stimulant users to "come down" after the use of stimulants such as amphetamines, methamphetamine, cocaine, and MDMA (ecstasy).[57][not in citation given]
One case history reported a woman detoxifying from a high dose of zolpidem experiencing a generalized seizure, with clinical withdrawal and dependence effects reported to be similar to the benzodiazepine withdrawal syndrome.[58]
Nonmedical use of zolpidem is increasingly common in U.S.A, Canada, and the UK. Recreational users report that resisting the drug's hypnotic effects can in some cases elicit vivid visuals and a body high.[59] Some users have reported decreased anxiety, mild euphoria, perceptual changes, visual distortions, and hallucinations.[60]
Other drugs, including the benzodiazepines and zopiclone, are also found in high numbers of suspected drugged drivers. Many drivers have blood levels far exceeding the therapeutic dose range suggesting a high degree of excessive-use potential for benzodiazepines, zolpidem and zopiclone.[61] U.S. Congressman Patrick J. Kennedy says that he was using Zolpidem (Ambien) and Phenergan when caught driving erratically at 3AM.[62] "I simply do not remember getting out of bed, being pulled over by the police, or being cited for three driving infractions," Kennedy said.
Zolpidem, along with the other benzodiazepine-like Z-drugs, is a Schedule IV controlled substance in the USA, according to the Controlled Substances Act, given its potential for abuse and dependence.

Date-rape drug

According to the U.S. Drug Enforcement Administration, zolpidem (Ambien, Stilnox) is quickly overtaking illegal sedatives as the most common date-rape drug. Perpetrators of sexual assault have used zolpidem on unsuspecting victims.[63][64]
With more than 250,000 prescriptions written in the last year, zolpidem is more accessible to potential sexual abusers than rohypnol, or "roofies," and its side effects when mixed with alcohol can exacerbate the sedative effects.

Research

Zolpidem may provide short-lasting but effective improvement in symptoms of aphasia present in some survivors of stroke. The mechanism for improvement in these cases remains unexplained and is the focus of current research by several groups, to explain how a drug which acts as a hypnotic-sedative in people with normal brain function, can paradoxically increase speech ability in people recovering from severe brain injury. Use of zolpidem for this application remains experimental at this time, and is not officially approved by any pharmaceutical manufacturers of zolpidem or medical regulatory agencies worldwide.[65][66][67][68][69]

Saturday, July 7, 2012

Higgs Boson News

Higgs boson

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Higgs boson
CMS Higgs-event.jpg
One possible signature of a Higgs boson from a simulated proton–proton collision. It decays almost immediately into two jets of hadrons and two electrons, visible as lines.[Note 1]
Composition Elementary particle
Statistics Bosonic
Status Tentatively observed – a boson "consistent with" the Higgs boson has been observed, but as of July 2012, scientists have not conclusively identified it as the Higgs boson.[1]
Symbol H0
Theorised R. Brout, F. Englert, P. Higgs, G. S. Guralnik, C. R. Hagen, and T. W. B. Kibble (1964)
Discovered a compatible particle has been observed by ATLAS and CMS (2012)
Types 1 in the Standard Model;
5 or more in supersymmetric models
Mass 125.3±0.6 GeV/c2,[2]126 GeV/c2[3]
Electric charge 0
Spin 0
The Higgs boson or Higgs particle is a proposed elementary particle in the Standard Model of particle physics. The Higgs boson is named after Peter Higgs who, along with others, proposed the mechanism that predicted such a particle in 1964.[4][5][6] The existence of the Higgs boson and the associated Higgs field explain why the other massive elementary particles in the standard model have their mass. In this theory, the Higgs field has a non-zero field everywhere, even in its lowest energy state. Other massive elementary particles obtain mass through the continuous interaction with this field (however, not all elementary particles have mass). The Higgs field interaction is the simplest mechanism which explains why some elementary particles have mass. The Higgs boson—the smallest possible excitation of the Higgs field—has been the target of a long search in particle physics. One of the primary design goals of the Large Hadron Collider at CERN in Geneva, Switzerland—one of the most complicated scientific instruments ever built—was to test the existence of the Higgs boson and measure its properties.
Because of its role in a fundamental property of elementary particles, the Higgs boson has been referred to as the "God particle" in popular culture, although virtually all scientists regard this as a hyperbole. According to the Standard Model, the Higgs particle is a boson, a type of particle that allows multiple identical particles to exist in the same place in the same quantum state. Furthermore, the model posits that the particle has no intrinsic spin, no electric charge, and no colour charge. It is also very unstable, decaying almost immediately after its creation.
On 4 July 2012, the CMS and the ATLAS experimental collaborations at the Large Hadron Collider announced that they observed a new boson that is consistent with the Higgs boson, noting that further data and analysis were needed before the particle could be positively identified.

Contents

Overview

The existence of the Higgs boson was predicted in 1964 to explain the Higgs mechanism (sometimes termed in the literature the Brout–Englert–Higgs, BEH or Brout–Englert–Higgs–Hagen–Guralnik–Kibble mechanism after its original proposers[7])—the mechanism by which elementary particles are given mass.[Note 2] While the Higgs mechanism is considered confirmed to exist, the boson itself—a cornerstone of the leading theory—had not been observed and its existence was unconfirmed. Its tentative discovery in July 2012 may validate the Standard Model as essentially correct, as it is the final elementary particle predicted and required by the Standard Model which had not yet been observed via particle physics experiments.[8] Alternative sources of the Higgs mechanism that do not need the Higgs boson also are possible and would be considered if the existence of the Higgs boson were to be ruled out. They are known as Higgsless models.
The Higgs boson is named after Peter Higgs, who in 1964 wrote one of three ground-breaking papers alongside the work of Robert Brout and François Englert and Tom Kibble, C. R. Hagen and Gerald Guralnik covering what is now known as the Higgs mechanism and described the related Higgs field and boson.
Technically, it is the quantum excitation of the Higgs field, and the non-zero value of the ground state of this field, that give mass to the other elementary particles, such as quarks and electrons. The Standard Model completely fixes the properties of the Higgs boson, except for its mass. It is expected to have no spin and no electric or colour charge, and it interacts with other particles through the weak interaction and Yukawa-type interactions between the various fermions and the Higgs field.
Because the Higgs boson is a very massive particle and decays almost immediately when created, only a very high-energy particle accelerator can observe and record it. Experiments to confirm and determine the nature of the Higgs boson using the Large Hadron Collider (LHC) at CERN began in early 2010, and were performed at Fermilab's Tevatron until its close in late 2011. Mathematical consistency of the Standard Model requires that any mechanism capable of generating the masses of elementary particles become visible at energies above 1.4 TeV;[9] therefore, the LHC (designed to collide two 7 TeV proton beams, but currently running at 4 TeV each) was built to answer the question of whether or not the Higgs boson exists.[10]
On 4 July 2012, the two main experiments at the LHC (ATLAS and CMS) both reported independently the confirmed existence of a previously unknown particle with a mass of about 125 GeV/c2 (about 133 proton masses, on the order of 10−25 kg), which is "consistent with the Higgs boson" and widely believed to be the Higgs boson. They cautioned that further work would be needed to confirm that it is indeed the Higgs boson (meaning that it has the theoretically predicted properties of the Higgs boson and is not some other previously unknown particle) and, if so, to determine which version of the Standard Model it best supports.[1][2][3][11][12]

General description

In particle physics, elementary particles and forces give rise to the world around us. Physicists explain the behaviours of these particles and how they interact using the Standard Model—a widely accepted framework believed to explain most of the world we see around us.[13] Initially, when these models were being developed and tested, it seemed that the mathematics behind those models, which were satisfactory in areas already tested, would also forbid elementary particles from having any mass, which showed clearly that these initial models were incomplete. In 1964 three groups of physicists almost simultaneously released papers describing how masses could be given to these particles, using approaches known as symmetry breaking. This approach allowed the particles to obtain a mass, without breaking other parts of particle physics theory that were already believed reasonably correct. This idea became known as the Higgs mechanism (not the same as the boson), and later experiments confirmed that such a mechanism does exist—but they could not show exactly how it happens.
The leading and simplest theory for how this effect takes place in nature was that if a particular kind of "field" (known as a Higgs field) happened to permeate space, and if it could interact with fundamental particles in a particular way, then this would give rise to a Higgs mechanism in nature, and would therefore create around us the phenomenon we call "mass". During the 1960s and 1970s the Standard Model of physics was developed on this basis, and it included a prediction and requirement that for these things to be true, there had to be an undiscovered boson—one of the fundamental particles—as the counterpart of this field. This would be the Higgs boson. If the Higgs boson were confirmed to exist, as the Standard Model suggested, then scientists could be satisfied that the Standard Model was fundamentally correct. If the Higgs boson were proved not to exist, then other theories would be considered as candidates instead.
The Standard Model also made clear that the Higgs boson would be very difficult to demonstrate. It exists for only a tiny fraction of a second before breaking up into other particles—so quickly that it cannot be directly detected—and can be detected only by identifying the results of its immediate decay and analysing them to show they were probably created from a Higgs boson and not some other source. The Higgs boson requires so much energy to create (compared to many other fundamental particles) that it also requires a massive particle accelerator to create collisions energetic enough to create it and record the traces of its decay. Given a suitable accelerator and appropriate detectors, scientists can record trillions of particles colliding, analyse the data for collisions likely to be a Higgs boson, and then perform further analysis to test how likely it is that the results combined show a Higgs boson does exist, and that the results are not just due to chance.
Experiments to try to show whether the Higgs boson did or did not exist began in the 1980s, but until the 2000s it could only be said that certain areas were plausible, or ruled out. In 2008 the Large Hadron Collider (LHC) was inaugurated, being the most powerful particle accelerator ever built. It was designed especially for this experiment, and other very-high-energy tests of the Standard Model. In 2010 it began its primary research role: to prove whether or not the Higgs boson exists.
In late 2011 two of the LHC's experiments independently began to suggest "hints" of a Higgs boson detection around 125 GeV. In July 2012 CERN announced[1] evidence of discovery of a boson with an energy level and other properties consistent with those expected in a Higgs boson. Further work is necessary for the evidence to be considered conclusive (or disproved). If the newly discovered particle is indeed the Higgs boson, attention will turn to considering whether its characteristics match one of the extant versions of the Standard Model. The CERN data include clues that additional bosons or similar-mass particles may have been discovered as well as, or instead of, the Higgs itself. If a different boson were confirmed, it would allow and require the development of new theories to supplant the current Standard Model.

History

AIP-Sakurai-best.JPG  Higgs, Peter (1929) cropped.jpg
The six authors of the 1964 PRL papers, who received the 2010 J. J. Sakurai Prize for their work. From left to right: Kibble, Guralnik, Hagen, Englert, Brout. Right: Higgs.
Particle physicists study matter made from fundamental particles whose interactions are mediated by exchange particles known as force carriers. At the beginning of the 1960s a number of these particles had been discovered or proposed, along with theories suggesting how they relate to each other; however, even accepted versions such as the Unified field theory were known to be incomplete. One omission was that they could not explain the origins of mass as a property of matter. Goldstone's theorem, relating to continuous symmetries within some theories, also appeared to rule out many obvious solutions.[14]
The Higgs mechanism is a process by which vector bosons can get rest mass without explicitly breaking gauge invariance. The proposal for such a spontaneous symmetry breaking mechanism originally was suggested in 1962 by Philip Warren Anderson[15] and developed into a full relativistic model, independently and almost simultaneously, by three groups of physicists: by François Englert and Robert Brout in August 1964;[16] by Peter Higgs in October 1964;[17] and by Gerald Guralnik, C. R. Hagen, and Tom Kibble (GHK) in November 1964.[18] Properties of the model were further considered by Guralnik in 1965 [19] and by Higgs in 1966.[20] The papers showed that when a gauge theory is combined with an additional field that spontaneously breaks the symmetry group, the gauge bosons can consistently acquire a finite mass. In 1967, Steven Weinberg and Abdus Salam were the first to apply the Higgs mechanism to the breaking of the electroweak symmetry, and showed how a Higgs mechanism could be incorporated into Sheldon Glashow's electroweak theory,[21][22][23] in what became the Standard Model of particle physics.
The three papers written in 1964 were each recognised as milestone papers during Physical Review Letters's 50th anniversary celebration.[24] Their six authors were also awarded the 2010 J. J. Sakurai Prize for Theoretical Particle Physics for this work.[25] (A dispute also arose the same year; in the event of a Nobel Prize up to three scientists would be eligible, with six authors credited for the papers.[26] ) Two of the three PRL papers (by Higgs and by GHK) contained equations for the hypothetical field that eventually would become known as the Higgs field and its hypothetical quantum, the Higgs boson. Higgs's subsequent 1966 paper showed the decay mechanism of the boson; only a massive boson can decay and the decays can prove the mechanism.
In the paper by Higgs the boson is massive, and in a closing sentence Higgs writes that "an essential feature" of the theory "is the prediction of incomplete multiplets of scalar and vector bosons". In the paper by GHK the boson is massless and decoupled from the massive states. In reviews dated 2009 and 2011, Guralnik states that in the GHK model the boson is massless only in a lowest-order approximation, but it is not subject to any constraint and acquires mass at higher orders, and adds that the GHK paper was the only one to show that there are no massless Goldstone bosons in the model and to give a complete analysis of the general Higgs mechanism.[27][28]
In addition to explaining how mass is acquired by vector bosons, the Higgs mechanism also predicts the ratio between the W boson and Z boson masses as well as their couplings with each other and with the Standard Model quarks and leptons. Subsequently, many of these predictions have been verified by precise measurements performed at the LEP and the SLC colliders, thus overwhelmingly confirming that some kind of Higgs mechanism does take place in nature,[29] but the exact manner by which it happens has not yet been discovered. The results of searching for the Higgs boson are expected to provide evidence about how this is realized in nature.

Theoretical properties

Summary of interactions between particles described by the Standard Model.
A one-loop Feynman diagram of the first-order correction to the Higgs mass. The Higgs boson couples strongly to the top quark so it may, if heavy enough, decay into top–anti-top quark pairs.
The Standard Model predicts the existence of a field, called the Higgs field, which has a non-zero amplitude in its ground state; i.e. a non-zero vacuum expectation value. The existence of this non-zero vacuum expectation spontaneously breaks electroweak gauge symmetry which in turn gives rise to the Higgs mechanism. It is the simplest process capable of giving mass to the gauge bosons while remaining compatible with gauge theories.[citation needed] The field can be pictured as a pool of molasses that "sticks" to the otherwise massless fundamental particles that travel through the field, converting them into particles with mass that form (for example) the components of atoms. Its quantum would be a scalar boson, known as the Higgs boson.[citation needed]
In the Standard Model, the Higgs field consists of two neutral and two charged component fields. Both of the charged components and one of the neutral fields are Goldstone bosons, which act as the longitudinal third-polarization components of the massive W+, W, and Z bosons.[citation needed] The quantum of the remaining neutral component corresponds to (and is theoretically realised as) the massive Higgs boson. Since the Higgs field is a scalar field, the Higgs boson has no spin. The Higgs boson is also its own antiparticle and is CP-even, and has zero electric and colour charge.[30]
The Minimal Standard Model does not predict the mass of the Higgs boson.[31] If that mass is between 115 and 180 GeV/c2, then the Standard Model can be valid at energy scales all the way up to the Planck scale (1016 TeV).[citation needed] Many theorists expect new physics beyond the Standard Model to emerge at the TeV-scale, based on unsatisfactory properties of the Standard Model.[citation needed] The highest possible mass scale allowed for the Higgs boson (or some other electroweak symmetry breaking mechanism) is 1.4 TeV; beyond this point, the Standard Model becomes inconsistent without such a mechanism, because unitarity is violated in certain scattering processes.[citation needed]
In theory, the mass of the Higgs boson may be estimated indirectly. In the Standard Model, the Higgs boson has a number of indirect effects; most notably, Higgs loops result in tiny corrections to masses of W and Z bosons. Precision measurements of electroweak parameters, such as the Fermi constant and masses of W/Z bosons, can be used to constrain the mass of the Higgs. As of July 2011, the precision electroweak measurements tell us that the mass of the Higgs boson is lower than about 161 GeV/c2 at 95% confidence level (CL). This upper bound increases to 185 GeV/c2 when including the LEP-2 direct search lower bound of 114.4 GeV/c2.[29] These indirect constraints rely on the assumption that the Standard Model is correct. It may still be possible to discover a Higgs boson above 185 GeV/c2 if it is accompanied by other particles beyond those predicted by the Standard Model.[citation needed]
The Minimal Standard Model as described above contains only one complex isospin Higgs doublet, however, it also is possible to have an extended Higgs sector with additional doublets or triplets. The non-minimal Higgs sector favoured by theory are the two-Higgs-doublet models (2HDM), which predict the existence of a quintet of scalar particles: two CP-even neutral Higgs bosons h0 and H0, a CP-odd neutral Higgs boson A0, and two charged Higgs particles H±. The key method to distinguish different variations of the 2HDM models and the minimal SM involves their coupling and the branching ratios of the Higgs decays. The so called Type-I model has one Higgs doublet coupling to up and down quarks, while the second doublet does not couple to quarks. This model has two interesting limits, in which the lightest Higgs doesn't couple to either fermions (fermiophobic) or gauge bosons (gauge-phobic). In the 2HDM of Type-II, one Higgs doublet only couples to up-type quarks, while the other only couples to down-type quarks.
Many extensions to the Standard Model, including supersymmetry (SUSY), often contain an extended Higgs sector. Many supersymmetric models predict that the lightest Higgs boson will have a mass only slightly above the current experimental limits, at around 120 GeV/c2 or less.[citation needed] The heavily researched Minimal Supersymmetric Standard Model (MSSM) belongs to the class of models with a Type-II two-Higgs-doublet sector and could be ruled out by the observation of a Higgs belonging to a Type-I 2HDM.

Alternative mechanisms for electroweak symmetry breaking

In the years since the Higgs field and boson were proposed, several alternative models have been proposed by which the Higgs mechanism might be realised. The Higgs boson exists in some, but not all, theories. For example, it exists in the Standard Model and extensions such as the Minimal Supersymmetric Standard Model yet is not expected to exist in alternative models such as Technicolor. Models which do not include a Higgs field or a Higgs boson are known as Higgsless models. In these models, strongly interacting dynamics rather than an additional (Higgs) field produce the non-zero vacuum expectation value that breaks electroweak symmetry. A partial list of these alternative mechanisms are:
A goal of the LHC and Tevatron experiments is to distinguish between these models and determine if the Higgs boson exists or not.

Experimental search

Status as of March 2011.[citation needed] Coloured sections have been ruled out to the stated confidence intervals either by indirect measurements and LEP experiments (green) or by Tevatron experiments (orange).
Gluon-top-higgs.svg  BosonFusion-Higgs.svg
Feynman diagrams showing two ways the Higgs boson might be produced at the LHC. Left: two gluons convert to top/anti-top quark pairs, which combine. Right: two quarks emit W or Z bosons, which combine.
Like other massive particles (e.g. the top quark and W and Z bosons), Higgs bosons created in particle accelerators decay long before they reach any of the detectors. However, the Standard Model precisely predicts the possible modes of decay and their probabilities. This allows the creation of a Higgs boson to be shown by careful examination of the decay products of collisions. The experimental search therefore commenced in the 1980s with the opening of particle accelerators sufficiently powerful to provide evidence related to the Higgs boson.
Prior to the year 2000, data gathered at the Large Electron–Positron Collider (LEP) at CERN had allowed an experimental lower bound to be set for the mass of the Standard Model Higgs boson of 114.4 GeV/c2 at the 95% confidence level (CL). The same experiment has produced a small number of events that could be interpreted as resulting from Higgs bosons with a mass just above this cut off—around 115 GeV—but the number of events was insufficient to draw definite conclusions.[36] The LEP was shut down in 2000 due to construction of its successor, the Large Hadron Collider (LHC).
Full operation at the LHC was delayed for 14 months from its initial successful tests on 10 September 2008, until mid-November 2009,[37][38] following a magnet quench event nine days after its inaugural tests that damaged over 50 superconducting magnets and contaminated the vacuum system.[39] The quench was traced to a faulty electrical connection and repairs took several months;[40][41] electrical fault detection and rapid quench-handling systems were also upgraded.
At the Fermilab Tevatron, there were also ongoing experiments searching for the Higgs boson. As of July 2010, combined data from CDF and experiments at the Tevatron were sufficient to exclude the Higgs boson in the range 158-175 GeV/c2 at 95% CL.[42][43] Preliminary results as of July 2011 extended the excluded region to the range 156-177 GeV/c2 at 95% CL.[44]
Data collection and analysis in search of Higgs intensified from 30 March 2010 when the LHC began operating at 3.5 TeV.[45] Preliminary results from the ATLAS and CMS experiments at the LHC as of July 2011 excluded a Standard Model Higgs boson in the mass range 155-190 GeV/c2[46] and 149-206 GeV/c2,[47] respectively, at 95% CL. All of the above confidence intervals were derived using the CLs method.
As of December 2011 the search had narrowed to the approximate region 115–130 GeV, with a specific focus around 125 GeV, where both the ATLAS and CMS experiments had independently reported an excess of events,[48][49] meaning that a higher than expected number of particle patterns compatible with the decay of a Higgs boson were detected in this energy range. The data was insufficient to show whether or not these excesses were due to background fluctuations (i.e. random chance or other causes), and its statistical significance was not large enough to draw conclusions yet or even formally to count as an "observation", but the fact that two independent experiments had both shown excesses at around the same mass led to considerable excitement in the particle physics community.[50]
On 22 December 2011, the DØ collaboration also reported limitations on the Higgs boson within the Minimal Supersymmetric Standard Model, an extension to the Standard Model. Proton-antiproton (pp) collisions with a centre-of-mass energy of 1.96 TeV had allowed them to set an upper limit for Higgs boson production within MSSM ranging from 90 to 300 GeV, and excluding tanβ > 20–30 for masses of the Higgs boson below 180 GeV (tanβ is the ratio of the two Higgs doublet vacuum expectation values).[51]
At the end of December 2011, it was therefore widely expected that the LHC would provide sufficient data to either exclude or confirm the existence of the Standard Model Higgs boson by the end of 2012, when their 2012 collision data (at energies of 8 TeV) had been examined.[52]
Updates from the two LHC teams continued during the first part of 2012, with the tentative December 2011 data largely being confirmed and developed further. Updates were also available from the team analysing the final data from the Tevatron. All of these continued to highlight and narrow down the 125 GeV region as showing interesting features.
On 2 July 2012, the ATLAS collaboration published additional analyses of their 2011 data, excluding boson mass ranges of 111.4 GeV to 116.6 GeV, 119.4 GeV to 122.1 GeV, and 129.2 GeV to 541 GeV. They observed an excess of events corresponding to the Higgs boson mass hypotheses around 126 GeV with a local significance of 2.9 sigma.[53] On the same date, the DØ and CDF collaborations announced further analysis that increased their confidence. The significance of the excesses at energies between 115–140 GeV was now quantified as 2.9 standard deviations, corresponding to a 1 in 550 probability of being due to a statistical fluctuation. However, this still fell short of the 5 sigma confidence, therefore the results of the LHC experiments were necessary to establish a discovery. They excluded Higgs mass ranges at 100–103 and 147–180 GeV.[54][55]
On 22 June 2012 CERN announced an upcoming seminar covering tentative findings for 2012,[56][57] and shortly afterwards rumours began to spread in the media that this would include a major announcement, but it was unclear whether this would be a stronger signal or a formal discovery.[58][59] On 4 July 2012 CMS announced the discovery of a boson with mass 125.3 ± 0.6 GeV/c2 at a statistical significance of 4.9 sigma,[2] and ATLAS of a boson with mass 126.5 GeV/c2 at 5 sigma.[3] This meets the formal level required to announce a new particle which is "consistent with" the Higgs boson, but scientists have not positively identified it as being the Higgs boson, pending further data collection and analysis.[1]

Timeline of experimental evidence

All results refer to the Standard Model Higgs boson, unless otherwise stated.
  • 2000–2004 – using data collected before 2000, in 2003–2004 Large Electron–Positron Collider experiments published papers which set a lower bound for the Higgs boson of 114.4 GeV/c2 at the 95% confidence level (CL), with a small number of events around 115 GeV.[36]
  • July 2010 – data from CDF (Fermilab) and DØ (Tevatron) experiments exclude the Higgs boson in the range 158–175 GeV/c2 at 95% CL.[42][43]
  • 24 April 2011 – media reports "rumors" of a find;[60] these were debunked by May 2011.[61] They had not been a hoax, but were based on unofficial, unreviewed results.[62]
  • 24 July 2011 – the LHC reported possible signs of the particle, the ATLAS Note concluding: "In the low mass range (c. 120–140 GeV) an excess of events with a significance of approximately 2.8 sigma above the background expectation is observed" and the BBC reporting that "interesting particle events at a mass of between 140 and 145 GeV" were found.[63][64] These findings were repeated shortly thereafter by researchers at the Tevatron with a spokesman stating that: "There are some intriguing things going on around a mass of 140GeV."[63] On 22 August 2011 it was reported that these anomalous results had become insignificant on the inclusion of more data from ATLAS and CMS and that the non-existence of the particle had been confirmed by LHC collisions to 95% certainty between 145–466 GeV (except for a few small islands around 250 GeV).[65]
  • 23–24 July 2011 – Preliminary LHC results exclude the ranges 155–190 GeV/c2 (ATLAS)[46] and 149–206 GeV/c2 (CMS)[47] at 95% CL.
  • 27 July 2011 – preliminary CDF/DØ results extend the excluded range to 156–177 GeV/c2 at 95% CL.[44]
  • 18 November 2011 – a combined analysis of ATLAS and CMS data further narrowed the window for the allowed values of the Higgs boson mass to 114–141 GeV.[66]
  • 13 December 2011 – experimental results were announced from the ATLAS and CMS experiments, indicating that if the Higgs boson exists, its mass is limited to the range 116–130 GeV (ATLAS) or 115–127 GeV (CMS), with other masses excluded at 95% CL. Observed excesses of events at around 124 GeV (CMS) and 125–126 GeV (ATLAS) are consistent with the presence of a Higgs boson signal, but also consistent with fluctuations in the background. The global statistical significances of the excesses are 1.9 sigma (CMS) and 2.6 sigma (ATLAS) after correction for the look elsewhere effect.[48][49]
  • 22 December 2011 – the DØ collaboration also sets limits on Higgs boson masses within the Minimal Supersymmetric Standard Model (an extension of the Standard Model), with an upper limit for production ranging from 90 to 300 GeV, and excluding tanβ>20–30 for Higgs boson masses below 180 GeV at 95% CL.[51]
  • 7 February 2012 – updating the December results, the ATLAS and CMS experiments constrain the Standard Model Higgs boson, if it exists, to the range 116–131 GeV and 115–127 GeV, respectively, with the same statistical significance as before.[67][68][69]
  • 7 March 2012 – the DØ and CDF collaborations announced that they found excesses that might be interpreted as coming from a Higgs boson with a mass in the region of 115 to 135 GeV/c2 in the full sample of data from Tevatron. The significance of the excesses is quantified as 2.2 standard deviations, corresponding to a 1 in 250 probability of being due to a statistical fluctuation. This is a lower significance, but consistent with and independent of the ATLAS and CMS data at the LHC.[70][71] This new result also extends the range of Higgs-mass values excluded by the Tevatron experiments at 95% CL, which becomes 147-179 GeV/c2.[72][73]
  • 2 July 2012 – the ATLAS collaboration further analysed their 2011 data, excluding Higgs mass ranges of 111.4 GeV to 116.6 GeV, 119.4 GeV to 122.1 GeV, and 129.2 GeV to 541 GeV. Higgs bosons are probably located at 126 GeV with significance of 2.9 sigma.[53] On the same day, the DØ and CDF collaborations also announced further analysis, increasing their confidence that the data between 115–140 GeV is corresponding to a Higgs boson to 2.9 sigma, excluding mass ranges at 100–103 and 147–180 GeV.[54][55]
  • 4 July 2012 – the CMS collaboration "announces the discovery of a boson with mass 125.3 ± 0.6 GeV/c2 within 4.9 σ (sigma)" and the ATLAS collaboration announced that "we observe in our data clear signs of a new particle, at the level of 5 sigma, in the mass region around 126 GeV." These findings meet the formal level required to announce a new particle which is "consistent with" the Higgs boson, but scientists have not positively identified it as being the Higgs boson, pending further analysis.[1]

"God particle"

The Higgs boson is often referred to as the "God particle" by individuals outside the scientific community,[74] after the title of Leon Lederman's popular science book on particle physics, The God Particle: If the Universe Is the Answer, What Is the Question?[75][76] While use of this term may have contributed to increased media interest,[76] many scientists dislike it, since it is sensational and overstates the particle's importance. Its discovery would still leave unanswered questions about the unification of quantum chromodynamics, the electroweak interaction, and gravity, as well as the ultimate origin of the universe.[74][77] Higgs, an atheist himself, is displeased that the Higgs particle is nicknamed the "God particle",[78] because the term "might offend people who are religious".[79]
Lederman said he gave it a nickname because the particle is "so central to the state of physics today, so crucial to our understanding of the structure of matter, yet so elusive,"[74][75][80] and added that he chose "the God particle" because "the publisher wouldn't let us call it the Goddamn Particle, though that might be a more appropriate title, given its villainous nature and the expense it is causing."[75]
A renaming competition conducted by the science correspondent for the British Guardian newspaper chose the name "the champagne bottle boson" as the best from among their submissions: "The bottom of a champagne bottle is in the shape of the Higgs potential and is often used as an illustration in physics lectures. So it's not an embarrassingly grandiose name, it is memorable, and [it] has some physics connection too."[81]

 Source : http://en.wikipedia.org/wiki/Higgs_boson